269 related articles for article (PubMed ID: 36647536)
1. Advances in
Chen H; Lei P; Ji H; Yang Q; Peng B; Ma J; Fang Y; Qu L; Li H; Wu W; Jin L; Sun D
Mater Today Bio; 2023 Feb; 18():100543. PubMed ID: 36647536
[TBL] [Abstract][Full Text] [Related]
2. Escherichia coli Nissle 1917 ghosts alleviate inflammatory bowel disease in zebrafish.
Chen H; Lei P; Ji H; Ma J; Fang Y; Yu H; Du J; Qu L; Yang Q; Luo L; Zhang K; Wu W; Jin L; Sun D
Life Sci; 2023 Sep; 329():121956. PubMed ID: 37473802
[TBL] [Abstract][Full Text] [Related]
3. Escherichia coli Nissle 1917 bacterial ghosts retain crucial surface properties and express chlamydial antigen: an imaging study of a delivery system for the ocular surface.
Montanaro J; Inic-Kanada A; Ladurner A; Stein E; Belij S; Bintner N; Schlacher S; Schuerer N; Mayr UB; Lubitz W; Leisch N; Barisani-Asenbauer T
Drug Des Devel Ther; 2015; 9():3741-54. PubMed ID: 26229437
[TBL] [Abstract][Full Text] [Related]
4. Escherichia coli Nissle 1917-driven microrobots for effective tumor targeted drug delivery and tumor regression.
Wu D; Zhao Z; Liu H; Fu K; Ji Y; Ji W; Li Y; Yan Q; Yang G
Acta Biomater; 2023 Oct; 169():477-488. PubMed ID: 37532134
[TBL] [Abstract][Full Text] [Related]
5.
Zhang Y; Ji W; He L; Chen Y; Ding X; Sun Y; Hu S; Yang H; Huang W; Zhang Y; Liu F; Xia L
Theranostics; 2018; 8(6):1690-1705. PubMed ID: 29556350
[No Abstract] [Full Text] [Related]
6. Expressing cytotoxic compounds in Escherichia coli Nissle 1917 for tumor-targeting therapy.
Li R; Helbig L; Fu J; Bian X; Herrmann J; Baumann M; Stewart AF; Müller R; Li A; Zips D; Zhang Y
Res Microbiol; 2019 Mar; 170(2):74-79. PubMed ID: 30447257
[TBL] [Abstract][Full Text] [Related]
7. Construction and In Vitro Evaluation of a Tumor Acidic pH-Targeting Drug Delivery System Based on
Ma Y; Liu Q; Hu A; Jiang S; Wang S; Liu R; Han K; Wang J
Bioengineering (Basel); 2022 Sep; 9(9):. PubMed ID: 36134979
[TBL] [Abstract][Full Text] [Related]
8. Doxorubicin-conjugated Escherichia coli Nissle 1917 swimmers to achieve tumor targeting and responsive drug release.
Xie S; Zhao L; Song X; Tang M; Mo C; Li X
J Control Release; 2017 Dec; 268():390-399. PubMed ID: 29101053
[TBL] [Abstract][Full Text] [Related]
9. High density fermentation of probiotic E. coli Nissle 1917 towards heparosan production, characterization, and modification.
Datta P; Fu L; Brodfuerer P; Dordick JS; Linhardt RJ
Appl Microbiol Biotechnol; 2021 Feb; 105(3):1051-1062. PubMed ID: 33481068
[TBL] [Abstract][Full Text] [Related]
10. Prospective and challenges of live bacterial therapeutics from a superhero
Effendi SSW; Ng IS
Crit Rev Microbiol; 2023 Sep; 49(5):611-627. PubMed ID: 35947523
[No Abstract] [Full Text] [Related]
11. Genetic engineering of probiotic Escherichia coli Nissle 1917 for clinical application.
Ou B; Yang Y; Tham WL; Chen L; Guo J; Zhu G
Appl Microbiol Biotechnol; 2016 Oct; 100(20):8693-9. PubMed ID: 27640192
[TBL] [Abstract][Full Text] [Related]
12. Tumor Colonization and Therapy by
Gentschev I; Petrov I; Ye M; Kafuri Cifuentes L; Toews R; Cecil A; Oelschaeger TA; Szalay AA
Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551519
[TBL] [Abstract][Full Text] [Related]
13. Emerging strategies for engineering Escherichia coli Nissle 1917-based therapeutics.
Lynch JP; Goers L; Lesser CF
Trends Pharmacol Sci; 2022 Sep; 43(9):772-786. PubMed ID: 35232591
[TBL] [Abstract][Full Text] [Related]
14. [Escherichia coli Nissle 1917 as safe vehicles for intestinal immune targeted therapy--a review].
Xia P; Zhu J; Zhu G
Wei Sheng Wu Xue Bao; 2013 Jun; 53(6):538-44. PubMed ID: 24028055
[TBL] [Abstract][Full Text] [Related]
15. Intestinal probiotics
He L; Yang H; Tang J; Liu Z; Chen Y; Lu B; He H; Tang S; Sun Y; Liu F; Ding X; Zhang Y; Hu S; Xia L
J Biol Eng; 2019; 13():58. PubMed ID: 31297149
[TBL] [Abstract][Full Text] [Related]
16. Probiotic
Zhao Z; Xu S; Zhang W; Wu D; Yang G
Food Funct; 2022 Jun; 13(11):5914-5924. PubMed ID: 35583304
[No Abstract] [Full Text] [Related]
17. In vitro and in vivo uptake study of Escherichia coli Nissle 1917 bacterial ghosts: cell-based delivery system to target ocular surface diseases.
Stein E; Inic-Kanada A; Belij S; Montanaro J; Bintner N; Schlacher S; Mayr UB; Lubitz W; Stojanovic M; Najdenski H; Barisani-Asenbauer T
Invest Ophthalmol Vis Sci; 2013 Sep; 54(9):6326-33. PubMed ID: 23920373
[TBL] [Abstract][Full Text] [Related]
18. Plasmid Vectors for
Kan A; Gelfat I; Emani S; Praveschotinunt P; Joshi NS
ACS Synth Biol; 2021 Jan; 10(1):94-106. PubMed ID: 33301298
[No Abstract] [Full Text] [Related]
19. Construction of a new T7 promoter compatible Escherichia coli Nissle 1917 strain for recombinant production of heme-dependent proteins.
Fiege K; Frankenberg-Dinkel N
Microb Cell Fact; 2020 Oct; 19(1):190. PubMed ID: 33023596
[TBL] [Abstract][Full Text] [Related]
20. Probiotic Escherichia coli Nissle 1917-derived outer membrane vesicles enhance immunomodulation and antimicrobial activity in RAW264.7 macrophages.
Hu R; Lin H; Li J; Zhao Y; Wang M; Sun X; Min Y; Gao Y; Yang M
BMC Microbiol; 2020 Aug; 20(1):268. PubMed ID: 32854612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
